How we picked the 31 peptides in Peptora v1

When we started building Peptora we had a list of 80+ peptides we could include. The internet will happily tell you about all of them. Most apps shrug and just dump everything in.

We took the opposite approach. 31 peptides, picked deliberately. Here’s how we filtered.

The three tiers

We sorted candidates into three tiers based on how much evidence exists and how widely they’re actually used.

Tier 1 — well-established (must include)

Peptides with multiple human trials, established dosing protocols, and broad off-label use. Examples: BPC-157, Semaglutide, Tirzepatide, CJC-1295, Ipamorelin.

These get the most thorough treatment in the app — full beginner/standard/advanced protocols, detailed side effect lists, and contraindication notes.

Tier 2 — emerging consensus (most should include)

Peptides with strong animal data and at least one human pilot study, plus growing community adoption. Examples: TB-500, GHK-Cu, Tesamorelin, Selank, Semax, MOTS-c.

These get full protocol coverage but with explicit “research-only” framing throughout.

Tier 3 — research-grade / emerging (include only the most-asked)

Peptides where the science is interesting but human data is sparse. Examples: Humanin, Klotho, SS-31, Cerebrolysin, Kisspeptin-10.

These get conservative protocols and clear warnings that long-term safety is unknown in humans.

What didn’t make the cut

A few peptides we considered but excluded for v1:

• Frag 176-191 — we included AOD-9604 instead since it’s the same fragment with better trial data.
• HCG — not really a “research peptide” in the modern sense; it’s a long-established hormone.
• IGF-1 LR3 — too narrow a use case, and cancer-risk profile makes us uncomfortable shipping default protocols.
• Various nootropics like NSI-189 — they’re not peptides.

What’s coming in v2

We’re tracking ~10 candidates for the next wave:

• 5-Amino-1MQ — NNMT inhibitor, fat loss research
• GHRP-6 — the older sibling of GHRP-2 we shipped
• Mod GRF 1-29 — close cousin of CJC-1295
• Tesofensine — appetite suppressant, Phase 3 data growing
• VIP — vasoactive intestinal peptide, anti-inflammatory research

If you want one prioritized, let us know via the app’s Settings → Send feedback.

Why this matters

Apps that list 100+ compounds without curation aren’t doing research — they’re listing. The filtering is the value-add. If a peptide is in Peptora it’s because the dosing math, side effect profile, and contraindications are well enough understood that we’d feel OK shipping a protocol for it.

If something’s missing, that’s an editorial choice — not an oversight.